Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
Ein echter Gamechanger: Diese News kann den Grundstein für eine Neubewertung der Rock-Tech-Aktie legen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40SY6 | ISIN: US53630L2097 | Ticker-Symbol:
NASDAQ
18.06.25 | 21:33
2,380 US-Dollar
+3,48 % +0,080
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
LIPELLA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
LIPELLA PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur LIPELLA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting35PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases...
► Artikel lesen
LIPELLA PHARMACEUTICALS Aktie jetzt für 0€ handeln
MiLIPELLA PHARMACEUTICALS INC. - 8-K, Current Report1
FrLipella stock tumbles after Nasdaq delisting over rule violations2
FrNasdaq streicht Lipella Pharmaceuticals wegen Regelverstößen von der Börse3
FrLipella-Aktie stürzt nach Nasdaq-Delisting wegen Regelverstößen ab1
FrNasdaq delists Lipella Pharmaceuticals over rule violations1
FrLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market84PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases...
► Artikel lesen
17.06.Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology1
17.06.Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology166PITTSBURGH, June 17, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases...
► Artikel lesen
16.06.LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report1
04.06.Lipella Re-Signs Manufacturing Collaboration Agreement with Cook MyoSite3
04.06.Lipella Pharmaceuticals extends manufacturing pact with Cook MyoSite1
04.06.Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development96PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases...
► Artikel lesen
15.05.LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report1
14.05.LIPELLA PHARMACEUTICALS INC. - 10-Q, Quarterly Report1
22.04.Lipella Pharmaceuticals Inc.: Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 202584Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward...
► Artikel lesen
14.04.LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report3
08.04.Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus118PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies...
► Artikel lesen
07.04.LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report1
31.03.Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast1
Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1